While analysis of publicly-traded psychedelics companies can give us a good idea of the overall downward pressure on stock prices and thus valuations1, a look at the broader fundraising environment provides a more holistic view of the financial health of psychedelic endeavours. Here, we use in-house data to analyse funding activity throughout 2022. Part of our Year in Review series In 2022…


Previous articleExpanding ketamine’s horizons for rare neurological disorders
Next articleReunion Neuroscience Appoints Robert Alexander as Chief Medical Officer